CN113811296B - 用src激酶抑制剂治疗纤维化疾病或病症或间质性肺病的方法 - Google Patents

用src激酶抑制剂治疗纤维化疾病或病症或间质性肺病的方法 Download PDF

Info

Publication number
CN113811296B
CN113811296B CN202080016378.4A CN202080016378A CN113811296B CN 113811296 B CN113811296 B CN 113811296B CN 202080016378 A CN202080016378 A CN 202080016378A CN 113811296 B CN113811296 B CN 113811296B
Authority
CN
China
Prior art keywords
fibrosis
ipf
fibrotic
src kinase
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080016378.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN113811296A (zh
Inventor
L·库森斯
C·尼文斯
K·J·埃斯科特
S·蒙克利
A·普拉斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
AstraZeneca AB
Original Assignee
Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV, AstraZeneca AB filed Critical Fraunhofer Gesellschaft zur Foerderung der Angewandten Forschung eV
Publication of CN113811296A publication Critical patent/CN113811296A/zh
Application granted granted Critical
Publication of CN113811296B publication Critical patent/CN113811296B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202080016378.4A 2019-02-27 2020-02-26 用src激酶抑制剂治疗纤维化疾病或病症或间质性肺病的方法 Active CN113811296B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811009P 2019-02-27 2019-02-27
US62/811009 2019-02-27
PCT/IB2020/051642 WO2020174420A1 (en) 2019-02-27 2020-02-26 Method of treating a fibrotic disease or condition or of an interstitial lung disease using a src kinase inhibitor

Publications (2)

Publication Number Publication Date
CN113811296A CN113811296A (zh) 2021-12-17
CN113811296B true CN113811296B (zh) 2025-05-16

Family

ID=69784492

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080016378.4A Active CN113811296B (zh) 2019-02-27 2020-02-26 用src激酶抑制剂治疗纤维化疾病或病症或间质性肺病的方法

Country Status (12)

Country Link
US (1) US20220117966A1 (https=)
EP (1) EP3930715B1 (https=)
JP (2) JP7547356B2 (https=)
CN (1) CN113811296B (https=)
DK (1) DK3930715T3 (https=)
ES (1) ES2994095T3 (https=)
FI (1) FI3930715T3 (https=)
HU (1) HUE067967T2 (https=)
MA (1) MA55076A (https=)
PT (1) PT3930715T (https=)
TW (1) TWI836022B (https=)
WO (1) WO2020174420A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112674031B (zh) * 2020-12-03 2021-11-30 同济大学 新型冠状病毒感染的啮齿动物模型的构建方法和用途
US20250161250A1 (en) * 2022-02-28 2025-05-22 Nuformix Technologies Limited Compositions and methods for treatment of idiopathic pulmonary fibrosis
CN117618436A (zh) * 2022-08-25 2024-03-01 广州再极医药科技有限公司 一种稠环嘧啶类化合物的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530298A (zh) * 2015-01-26 2018-01-02 耶鲁大学 利用酪氨酸激酶抑制剂的组合物和方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
GB0427697D0 (en) 2004-12-17 2005-01-19 Astrazeneca Ab Chemical process
US9844528B2 (en) * 2006-08-24 2017-12-19 University Of Tennessee Research Foundation SARMs and method of use thereof
CN102675282B (zh) * 2011-03-15 2014-12-24 广东东阳光药业有限公司 取代的喹啉化合物及其使用方法和用途
US20130336889A1 (en) * 2012-06-14 2013-12-19 National Taiwan University Nanoparticle and method for detecting or treating a tumor using the same
CN105294682B (zh) * 2014-07-26 2017-07-07 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
EP3277282B1 (en) * 2015-04-01 2022-10-12 Istanbul Universitesi Rektorlugu Dasatinib for use in the treatment, regression or decelerating the progress of fibrotic lung diseases
GB201514760D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
JP6905662B2 (ja) * 2015-11-14 2021-07-21 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． 置換キノリン化合物の結晶形およびその医薬組成物
EP3228630A1 (en) * 2016-04-07 2017-10-11 IMBA-Institut für Molekulare Biotechnologie GmbH Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer
WO2018026441A1 (en) * 2016-08-01 2018-02-08 The Regents Of The University Of California Methods for preventing or treating fibrotic diseases
WO2018046876A1 (en) * 2016-09-06 2018-03-15 The University Of Birmingham Treatment of chronic inflammatory disease
CN106692150B (zh) * 2016-12-21 2019-08-20 中国人民解放军第三〇二医院 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途
EP3964214A1 (en) * 2020-09-02 2022-03-09 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. Modulators of airway basal cells for the treatment or prevention of lung diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107530298A (zh) * 2015-01-26 2018-01-02 耶鲁大学 利用酪氨酸激酶抑制剂的组合物和方法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice;Oznur Yilmaz;Growth Factors;第33卷(第5-6期);366-375 *
Nintedanib reduces ventilation-augmented bleomycin-induced epithelial–mesenchymal transition and lung fibrosis through suppression of the Src pathway;Li-Fu Li;Journal of Cellular and Molecular Medicine;第21卷(第11期);2937-2949 *
Oznur Yilmaz.Dasatinib attenuated bleomycin-induced pulmonary fibrosis in mice.Growth Factors.2015,第33卷(第5-6期),366-375. *
Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis;Ole Hilberg;The Clinical Respiratory Journal;第6卷(第3期);131-143 *

Also Published As

Publication number Publication date
CN113811296A (zh) 2021-12-17
PT3930715T (pt) 2024-08-02
ES2994095T3 (en) 2025-01-17
MA55076A (fr) 2022-04-20
DK3930715T3 (da) 2024-08-05
TWI836022B (zh) 2024-03-21
EP3930715B1 (en) 2024-05-08
HUE067967T2 (hu) 2024-12-28
JP2024174909A (ja) 2024-12-17
FI3930715T3 (fi) 2024-08-05
EP3930715A1 (en) 2022-01-05
JP2022521635A (ja) 2022-04-11
JP7547356B2 (ja) 2024-09-09
WO2020174420A1 (en) 2020-09-03
TW202045180A (zh) 2020-12-16
US20220117966A1 (en) 2022-04-21

Similar Documents

Publication Publication Date Title
ES2476368T3 (es) Tratamiento de la artritis reumatoide con una combinación de laquinimod y metotrexato
CN104245699B (zh) Nedd8‑活化酶抑制剂和低甲基化剂的投与
CN108430475B (zh) 用于治疗慢性咳嗽的奥维匹坦
CN113811296B (zh) 用src激酶抑制剂治疗纤维化疾病或病症或间质性肺病的方法
CN106488769A (zh) 用于治疗纤维化的赛尼克韦罗
EP4385571A2 (en) Uses of a lysyl oxidase-like 2 inhibitor related applications
AU2020293739B2 (en) Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof
US20140147415A1 (en) Treatment of mastocytosis with masitinib
TW201244716A (en) Combination of a phosphatidylinositol-3-kinase (PI3K) inhibitor and a mTOR inhibitor
KR102940911B1 (ko) 과민성 방광 증상의 치료를 위한 비베그론
US20220241294A1 (en) Bisfluoroalkyl-1,4-benzodiazepinone compounds for treating notch-activated breast cancer
JP2025509278A (ja) 小細胞肺癌を治療する方法
TW201841903A (zh) 末梢神經障礙之治療劑或預防劑
JP7442820B2 (ja) びまん性胃癌の治療剤
US10045978B2 (en) Treatment of mastocytosis with masitinib
TWI922768B (zh) 包含cdk4抑制劑之用於治療癌症之方法及給藥方案
Schmalzing et al. POS0640 REAL-WORLD EFFECTIVENESS AND SAFETY OF GP2015 IN PATIENTS WITH RHEUMATIC DISEASES: FINAL RESULTS OF THE COMPACT STUDY
Bertolaso et al. Drug interaction with Sunitinib and the evidence of therapeutic drug monitoring: a case report and review of the literature
EA051679B1 (ru) Комбинации лекарственных средств, содержащие ингибиторы тирозинкиназы рецептора met, и их применение
JP2024500628A (ja) 腫瘍治療のための４－アミノ－ｎ－［４－（メトキシメチル）フェニル］－７－（１－メチルシクロプロピル）－６－（３－モルホリノプロパ－１－イン－１－イル）－７ｈ－ピロロ［２，３－ｄ］ピリミジン－５－カルボキサミドの使用法
HK40110657A (zh) 用於治疗癌症的cdk4抑制剂
EA048593B1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant